Dexrazoxane protects breast cancer patients with diabetes from chemotherapy-induced cardiotoxicity

American Journal of the Medical Sciences

Volumn 349, Issue 5, 2015, Pages 406-412

  Sun, Fangyi ^a   Qi, Xiaoyong ^a,b   Geng, Cuizhi ^a   Li, Xingtao ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b HEBEI GENERAL HOSPITAL   (China)

Author keywords

Breast cancer; Cardiotoxicity; Chemotherapy; Dexrazoxane; Diabetes

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; MALONALDEHYDE; PLACEBO; RAZOXANE; SUPEROXIDE DISMUTASE; ANTINEOPLASTIC AGENT; CARDIOTONIC AGENT;

ADULT; ADVERSE DRUG REACTION; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CHEMOTHERAPY INDUCED CARDIOTOXICITY; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE DURATION; DRUG EFFECT; DRUG SAFETY; ECHOCARDIOGRAPHY; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HEMATOLOGY; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; BLOOD; BREAST NEOPLASMS; COMPLICATION; DRUG MONITORING; HEART FUNCTION TEST; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARDIOTONIC AGENTS; CARDIOTOXICITY; CYCLOPHOSPHAMIDE; DEXRAZOXANE; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; EPIRUBICIN; FEMALE; HEART FUNCTION TESTS; HUMANS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84928954588     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0000000000000432     Document Type: Article

References (44)

1. O'Shaughnessy J, Twelves C, Aapro M. Treatment for anthracycline-pretreated metastatic breast cancer. Oncologist 2002;7(suppl 6):4-12.
2. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869-79.
3. Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008;14:14-24.
4. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55:213-20.
5. Airoldi M, Amadori D, Barni S, et al. Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. Tumori 2011;97:690-2.
6. Khasraw M, Bell R, Dang C. Epirubicin: is it like doxorubicin in breast cancer? A clinical review. Breast 2012;21:142-9.
7. Tassan-Mangina S, Codorean D, Metivier M, et al. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr 2006;7:141-6.
8. Mercuro G, Cadeddu C, Piras A, et al. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist 2007;12:1124-33.
9. Lotrionte M, Cavarretta E, Abbate A, et al. Temporal changes in standard and tissue Doppler imaging echocardiographic parameters after anthracycline chemotherapy in women with breast cancer. Am J Cardiol 2013;112:1005-12.
10. Di Lisi D, Bonura F, Macaione F, et al. Chemotherapy-induced cardiotoxicity: role of the tissue Doppler in the early diagnosis of left ventricular dysfunction. Anticancer Drugs 2011;22:468-72.
11. Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006;48:2258-62.
12. Yu CM, Sanderson JE, Marwick TH, et al. Tissue Doppler imaging a new prognosticator for cardiovascular diseases. J Am Coll Cardiol 2007;49:1903-14.
13. Sanderson JE. Heart failure with a normal ejection fraction. Heart 2007;93:155-8.
14. Wang M, Yip G, Yu CM, et al. Independent and incremental prognostic value of early mitral annulus velocity in patients with impaired left ventricular systolic function. J Am Coll Cardiol 2005; 45:272-7.
15. Su HM, Lin TH, Voon WC, et al. Differentiation of left ventricular diastolic dysfunction, identification of pseudonormal/restrictive mitral inflow pattern and determination of left ventricular filling pressure by Tei index obtained from tissue Doppler echocardiography. Echocardiography 2006;23:287-94.
16. Erdogan D, Yucel H, Alanoglu EG, et al. Can comprehensive echocardiographic evaluation provide an advantage to predict anthracyclineinduced cardiomyopathy? Turk Kardiyol Dern Ars 2011;39:646-53.
17. Lopez M, Vici P, Di Lauro K, et al. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol 1998;16:86-92.
18. Swain SM, Whaley FS, Gerber MC, et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997; 15:1333-40.
19. Hasinoff BB. The interaction of the cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin. Agents Actions 1989;26:378-85.
20. Ichikawa Y, Ghanefar M, Bayeva M, et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest 2014;124:617-30.
21. Stěrba M, Popelová O, Vávrová A, et al. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal 2013;18: 899-929.
22. Dickey JS, Gonzalez Y, Aryal B, et al. Mito-tempol and dexrazoxane exhibit cardioprotective and chemotherapeutic effects through specific protein oxidation and autophagy in a syngeneic breast tumor preclinical model. PLoS One 2013;8:e70575.
23. Jirkovský E, Lenčová-Popelová O, Hroch M, et al. Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits. Toxicology 2013;311:191-204.
24. Marty M, Espie M, Llombart A, et al. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracyclinebased chemotherapy. Ann Oncol 2006;17:614-22.
25. Ryberg M, Nielsen D, Cortese G, et al. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 2008;100:1058-67.
26. Doyle JJ, Neugut AI, Jacobson JS, et al. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol 2005;23:8597-605.
27. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134-46.
28. Boyle P, Boniol M, Koechlin A, et al. Diabetes and breast cancer risk: a meta-analysis. Br J Cancer 2012;107:1608-17.
29. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
30. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echo-cardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63.
31. Erdogan D, Caliskan M, Yildirim I, et al. Effects of normal blood pressure, prehypertension and hypertension on left ventricular diastolic function and aortic elastic properties. Blood Press 2007;16:114-21.
32. Qi B, Ji Q, Wen Y, et al. Lycium barbarum polysaccharides protect human lens epithelial cells against oxidative stress-induced apoptosis and senescence. PLoS One 2014;9:e110275.
33. Jones LW, Haykowsky MJ, Swartz JJ, et al. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007;50: 1435-41.
34. Jones LW, Haykowsky M, Peddle CJ, et al. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab. Cancer Epidemiol Biomarkers Prev 2007;16:1026-31.
35. Jones LW, Haykowsky M, Pituskin EN, et al. Cardiovascular reserve and risk profile of postmenopausal women after chemoendocrine therapy for hormone receptor-positive operable breast cancer. Oncologist 2007;12:1156-64.
36. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-8.
37. Nunes S, Soares E, Fernandes J, et al. Early cardiac changes in a rat model of prediabetes: brain natriuretic peptide overexpression seems to be the best marker. Cardiovasc Diabetol 2013;12:44.
38. Miki T, Yuda S, Kouzu H, et al. Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev 2013;18:149-66.
39. Di Bonito P, Moio N, Cavuto L, et al. Early detection of diabetic cardiomyopathy: usefulness of tissue Doppler imaging. Diabet Med 2005;22:1720-5.
40. Simunek T, Sterba M, Popelova O, et al. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 2009;61:154-71.
41. Lebrecht D, Geist A, Ketelsen UP, et al. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol 2007;151:771-8.
42. Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012;18:1639-42.
43. Goldberg MA, Antin JH, Guinan EC, et al. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986;68:1114-8.
44. Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 2011;37:300-11.